Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

@article{Agnelli2012SemuloparinFT,
  title={Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.},
  author={Giancarlo Agnelli and Daniel J. George and Ajay K Kakkar and William D. Fisher and Michael Rud Lassen and Patrick Mismetti and Patrick Mouret and Umesh Chaudhari and Francesca C. Lawson and Alexander G G Turpie},
  journal={The New England journal of medicine},
  year={2012},
  volume={366 7},
  pages={
          601-9
        }
}
BACKGROUND Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism. Limited data support the clinical benefit of antithrombotic prophylaxis. METHODS In this double-blind, multicenter trial, we evaluated the efficacy and safety of the ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients receiving chemotherapy for cancer. Patients with metastatic or locally advanced solid tumors who were beginning to receive a… 

Figures and Tables from this paper

Thromboprophylaxis in patients receiving chemotherapy.

To the Editor: In their article on the results of the SAVE-ONCO study (ClinicalTrials.gov number, NCT00694382), which showed that semuloparin reduced the risks of deep-vein thrombosis in the lower or

Chemotherapy: Reduced incidence of major bleeds with semuloparin

Semuloparin, compared with placebo, reduces the incidence of venous thromboembolism in patients with locally advanced or metastatic cancer, with no apparent increase in major bleeding.

Primäre Thromboseprophylaxe bei Krebspatienten

  • C. Ay
  • Medicine, Biology
  • 2012
Risk stratification and identification of patients with high risk of VTE would be desirable to target prophylactic anticoagulation at those cancer patients who will benefit most.

Primäre Thromboseprophylaxe bei Krebspatienten

  • C. Ay
  • Medicine, Biology
  • 2012
Risk stratification and identification of patients with high risk of VTE would be desirable to target prophylactic anticoagulation at those cancer patients who will benefit most.

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer

The Guidelines focus on adult patients with active cancer and a clear indication for anticoagulation, single or dual antiplatelet therapy, their combination, or reperfusion therapy, who have concurrent thrombocytopenia because of either malignancy or anticancer medications.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

This update confirms that primary thromboprophylaxis with LMWH significantly reduced the incidence of symptomatic VTE in ambulatory cancer patients treated with chemotherapy and suggests that the quality of the evidence ranged from high to very low across the different outcomes and comparisons.

Efficacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis

Evidence is provided that thromboprophylaxis can reduce the number of VTE and DVT events, with no apparent increase in the incidence of major bleeding in patients with cancer.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Six additional randomised controlled trials were identified for this update, bringing the included study total to 32 (15,678 participants), all evaluating pharmacological interventions and performed mainly in people with locally advanced or metastatic cancer.
...

References

SHOWING 1-10 OF 52 REFERENCES

Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.

The annual incidence of VTE in patients treated with chemotherapy was high, specifically in patients with colorectal cancer treated with fluorouracil-leucovorin, and trials to evaluate the use of prophylactic anticoagulant treatment should be conducted.

Chemotherapy-induced thrombosis.

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, was associated with an increased risk of arterial thromboembolism but not venous thrombosis, and Baseline or on-study aspirin use wasassociated with modest increases in grade 3 and 4 bleeding events.

Thrombotic events in patients with cancer receiving antiangiogenesis agents.

Close attention to hemostatic complications during antiangiogenic treatment is warranted and further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy.

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

  • H. HurwitzL. Saltz U. Rohr
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
The addition of bevacizumab to chemotherapy did not statistically significantly increase the risk of venous thromboembolism versus chemotherapy alone and the risk for VTEs is driven predominantly by tumor and host factors.

Prediction of venous thromboembolism in cancer patients.

Clinical and standard laboratory parameters with addition of biomarkers enable prediction of VTE and allow identification of cancer patients at high or low risk of V TE.

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

The use of bevacizumab was significantly associated with an increased risk of developing venous thromboembolism in cancer patients receiving this drug.

Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.

Chemotherapy results in significant hemostatic activation in patients with breast and lung cancer and a single dose of a low molecular weight heparin, dalteparin sodium, administered prior to the chemotherapy can suppress he mostatic activation.
...